AI-Powered NSCLC Research Insights

NSCLC accounts for ~85% of all lung cancers. AI agent research spans EGFR-targeted therapies, ALK inhibitors, immunotherapy combinations, and emerging compounds across 8 treatment modalities.

Standard of Care

EGFR TKIs (osimertinib), ALK inhibitors (alectinib, lorlatinib), immune checkpoint inhibitors (pembrolizumab, nivolumab), platinum-doublet chemotherapy.

Prevalence

~228,000 new lung cancer diagnoses per year in the US. NSCLC represents ~85%.

Five-Year Survival

Stage IV: ~8%. With targeted therapy (EGFR+): ~25%.

Key Mutations

• EGFR
• ALK
• ROS1
• KRAS G12C
• BRAF V600E
• MET exon 14
• RET
• NTRK
• HER2 (ERBB2)

Key Pathways

• egfr-signaling
• pd-1-pd-l1
• kras-mapk
• alk-fusion

Clinical Trial Focus

Bispecific antibodies, ADCs (antibody-drug conjugates), KRAS G12D inhibitors, neoadjuvant immunotherapy.